Health Secretary Robert F. Kennedy Jr. has just flipped the script on federal vaccine policy with a decision that’s raising eyebrows across the medical world.
According to the Daily Mail, Kennedy’s newly formed vaccine advisory panel, the Advisory Committee on Immunization Practices (ACIP), voted 5-1 to push for flu shots without thimerosal, a mercury-based preservative, ignoring decades of scientific consensus on its safety, while his earlier move to fire all 17 previous panel members and replace them with a smaller, skeptic-heavy group has sparked a firestorm of debate.
Let’s rewind a bit to earlier this month when Kennedy, known for his long-standing doubts about vaccine ingredients, sacked the entire 17-member ACIP and handpicked a new seven-person team.
This new crew, including several vocal vaccine skeptics, didn’t waste time making waves. Their Thursday vote to discourage thimerosal in flu shots—a preservative already absent from over 95% of doses—feels like a solution in search of a problem.
Thimerosal has been studied exhaustively, with scientists and the FDA affirming it poses no health risk. Yet, anti-vaccine groups have peddled claims linking it to autism for years, despite study after study debunking any connection. It’s curious how fear can outmuscle facts in these debates.
“There is still no demonstrable evidence of harm,” admitted Dr. Joseph Hibbeln, a former National Institutes of Health psychiatrist on the panel. But then he added, respecting public fear of mercury might be worth humoring. Respecting fear over science—now there’s a slippery slope for public health.
Adding fuel to the fire, a CDC report confirming thimerosal’s safety was mysteriously pulled from the ACIP website before the vote, reportedly on orders from Kennedy’s office. Panel members confirmed they’d seen the data, yet it didn’t sway the 5-1 outcome. If you’re going to make a bold call, shouldn’t all the cards be on the table?
Medical groups aren’t holding back their criticism, pointing to a lack of openness. “Selective use of data and omission of established science undermines public trust,” warned Dr. Sean O´Leary of the American Academy of Pediatrics. When trust in vaccines is already shaky—with fewer than half of Americans getting yearly flu shots—this kind of opacity is a gut punch.
Outside the CDC headquarters in Atlanta, demonstrators rallied during the meeting, voicing support for the agency and frustration with Kennedy’s overhaul. Meanwhile, inside, Lyn Redwood, a nurse practitioner tied to Kennedy’s past anti-vaccine efforts, presented claims labeling thimerosal a neurotoxin. Her talk omitted a prior reference to a nonexistent study, raising questions about rigor.
The thimerosal decision, while affecting only a tiny fraction of flu vaccines, has broader implications, argue public health experts. They worry it plants unnecessary seeds of doubt at a time when vaccine hesitancy is climbing. Why poke the bear when the science is settled?
“The risk from influenza is so much greater than the nonexistent risk from thimerosal,” argued Dr. Cody Meissner, the lone dissenter in the vote. His point cuts deep—why risk scaring folks off a life-saving shot over a non-issue? It’s a classic case of ideology clouding common sense.
The ACIP meeting wasn’t just about flu shots; it also tackled other vaccines, like Merck’s new RSV antibody drug for infants, which passed 5-2 despite safety concerns from one panelist. Chairman Martin Kulldorff hinted at revisiting the children’s vaccine schedule and even newborn hepatitis B shots, ideas that echo debunked fears of “over-vaccination.” Pediatricians counter that kids today face fewer antigens than past generations, despite more doses.
Kennedy himself bypassed the panel to declare that COVID-19 vaccines won’t be recommended for healthy kids or pregnant women, directly contradicting CDC data on their protective benefits. This unilateral move, alongside the panel’s direction, has doctors like former adviser Dr. Fiona Havers calling the process a “farce.” When policy ignores evidence, who’s really being served?
As the ACIP plans its next meeting for the third quarter, per CDC schedules, the medical community braces for more upheaval. With no CDC director in place and President Trump’s nominee, Susan Monarez, still awaiting Senate confirmation, the path forward for these recommendations—needing final approval from either the director or Kennedy himself—remains murky. One thing’s clear: the battle over vaccine trust isn’t cooling down anytime soon.
